Quantcast

Latest Monoclonal antibodies Stories

2014-07-30 16:29:22

TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the Companies intend to use a U.S. Food and Drug Administration (FDA) rare pediatric disease priority review voucher in connection with the Biologics License Application (BLA) submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited...

2014-07-29 23:00:54

The factors contributing to sample preparation market growth are the improvements in the funding scenario globally, increase in the number of government sponsored research activities, and developments in drug discovery research. http://www.marketsandmarkets.com/Market-Reports/sample-preparation-market-66938505.html (PRWEB) July 30, 2014 This report studies the "Sample Preparation Market by Product (Instruments (Workstations, Liquid Handling Systems), Consumables (Tubes), Kits...

2014-07-29 08:32:17

Three new tools for bacterial detection and isolation MILFORD, Mass., July 29, 2014 /PRNewswire/ -- KPL, a SeraCare Company, today announced the addition of three new products to its growing line of BacTrace antibodies: BacTrace(®) Antibody Coated Latex Beads, BacTrace(®) STEC Antibodies, and BacTrace(®) Salmonella CSA-Plus Antibodies. These tools are designed for use by researchers and developers of foodborne pathogen assays. As polyclonals, the BacTrace antibodies can be used as...

2014-07-24 16:24:29

Emerging Therapies, Especially IL-17 Inhibitors, Have Potential Relative to Current Therapies in Improving Psoriatic Plaques, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis....

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-07-24 08:33:35

MONROVIA, Calif., July 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter financial results after market close on Thursday, July 31, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial...

2014-07-22 12:27:43

Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few...

2014-07-21 08:30:52

LONDON, July 21, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global Antibody Drug Conjugate Market Outlook 2018https://www.reportbuyer.com/product/2048454/Global-Antibody-Drug-Conjugate-Market-Outlook-2018.html The ADC technology is not new. It dates back to the 90s. However, several issues such as specificity of the payload (drug), and poor conjugation of drug and antibody proved a setback. But, the past few years have witnessed ADCs make a glorious...

2014-07-17 08:29:29

Nearly half a million dollars given to early-career physicians to study psoriatic disease PORTLAND, Ore., July 17, 2014 /PRNewswire-USNewswire/ -- Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis and psoriatic arthritis as...

2014-07-15 08:28:23

MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors. Mr. Gustafson will also serve as chair of Xencor's audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R....


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related